SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

This trial is testing SynKIR-110, a new type of engineered immune cell therapy (similar to CAR-T), for people with certain advanced cancers that carry a protein called mesothelin on the tumor surface. These cancers include ovarian cancer, bile duct cancer (cholangiocarcinoma), and the lining cancer mesothelioma. **You may be eligible if...** - You are 18 or older - You have confirmed recurrent or advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma - You have received at least one prior treatment line for advanced disease - You have measurable disease on imaging - You are in good overall health (ECOG 0 or 1) - Your blood clotting and organ function meet study requirements **You may NOT be eligible if...** - You have another active invasive cancer not in remission for at least 5 years - You have a history of T or B cell blood cancer, or have had prior gene-engineered T cell therapy - You have sarcomatoid or biphasic mesothelioma - You have active hepatitis B, hepatitis C, or HIV - You have an active autoimmune disease or inherited immune deficiency Talk to your doctor to see if this trial is right for you.